BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment ...

Eisai (ESAIY) and Biogen (BIIB) announced that Health Canada has issued a Notice of Compliance with Conditions for humanized ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

A groundbreaking Northwestern study shows how “SuperAgers" keep the memory abilities of people decades younger, uncovering ...

Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased ...

Alzheimer’s disease not only damages memory but also distorts the brain’s internal clock, disrupting the daily rhythms of hundreds of genes tied to brain health.

Johns Hopkins scientists found that neurons form tiny nanotube networks to transport toxins like amyloid-beta.

A new study has found that people with an impaired glymphatic system, which helps the brain remove toxins and is mostly ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

Researchers at the University of California, Irvine, have uncovered an unexpected molecular partnership that reshapes ...

Researchers at the University of California, Irvine, have uncovered an unexpected molecular partnership that reshapes scientists' understanding of how brain inflammation arises in Alzheimer's disease.